Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

US Paraganglioma Market

ID: MRFR/Pharma/18454-HCR
100 Pages
Satyendra Maurya
Last Updated: April 06, 2026

US Paraganglioma Market Research Report By Type (Functional Paraganglioma, Non-Functional Paraganglioma, Metastatic Paraganglioma), By Diagnosis Method (Imaging Techniques, Biopsy, Blood Tests), By Treatment (Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy) and By End User (Hospitals, Diagnostic Laboratories, Research Institutes) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

US Paraganglioma Market Infographic
Purchase Options
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Construction, BY Type (USD Million)
  49.     4.1.1 Functional Paraganglioma
  50.     4.1.2 Non-Functional Paraganglioma
  51.     4.1.3 Metastatic Paraganglioma
  52.   4.2 Construction, BY Diagnosis Method (USD Million)
  53.     4.2.1 Imaging Techniques
  54.     4.2.2 Biopsy
  55.     4.2.3 Blood Tests
  56.   4.3 Construction, BY Treatment (USD Million)
  57.     4.3.1 Surgery
  58.     4.3.2 Radiation Therapy
  59.     4.3.3 Chemotherapy
  60.     4.3.4 Targeted Therapy
  61.   4.4 Construction, BY End User (USD Million)
  62.     4.4.1 Hospitals
  63.     4.4.2 Diagnostic Laboratories
  64.     4.4.3 Research Institutes
  65. 5 SECTION V: COMPETITIVE ANALYSIS
  66.   5.1 Competitive Landscape
  67.     5.1.1 Overview
  68.     5.1.2 Competitive Analysis
  69.     5.1.3 Market share Analysis
  70.     5.1.4 Major Growth Strategy in the Construction
  71.     5.1.5 Competitive Benchmarking
  72.     5.1.6 Leading Players in Terms of Number of Developments in the Construction
  73.     5.1.7 Key developments and growth strategies
  74.       5.1.7.1 New Product Launch/Service Deployment
  75.       5.1.7.2 Merger & Acquisitions
  76.       5.1.7.3 Joint Ventures
  77.     5.1.8 Major Players Financial Matrix
  78.       5.1.8.1 Sales and Operating Income
  79.       5.1.8.2 Major Players R&D Expenditure. 2023
  80.   5.2 Company Profiles
  81.     5.2.1 Novartis (CH)
  82.       5.2.1.1 Financial Overview
  83.       5.2.1.2 Products Offered
  84.       5.2.1.3 Key Developments
  85.       5.2.1.4 SWOT Analysis
  86.       5.2.1.5 Key Strategies
  87.     5.2.2 Bristol-Myers Squibb (US)
  88.       5.2.2.1 Financial Overview
  89.       5.2.2.2 Products Offered
  90.       5.2.2.3 Key Developments
  91.       5.2.2.4 SWOT Analysis
  92.       5.2.2.5 Key Strategies
  93.     5.2.3 AstraZeneca (GB)
  94.       5.2.3.1 Financial Overview
  95.       5.2.3.2 Products Offered
  96.       5.2.3.3 Key Developments
  97.       5.2.3.4 SWOT Analysis
  98.       5.2.3.5 Key Strategies
  99.     5.2.4 Eli Lilly and Company (US)
  100.       5.2.4.1 Financial Overview
  101.       5.2.4.2 Products Offered
  102.       5.2.4.3 Key Developments
  103.       5.2.4.4 SWOT Analysis
  104.       5.2.4.5 Key Strategies
  105.     5.2.5 Merck & Co. (US)
  106.       5.2.5.1 Financial Overview
  107.       5.2.5.2 Products Offered
  108.       5.2.5.3 Key Developments
  109.       5.2.5.4 SWOT Analysis
  110.       5.2.5.5 Key Strategies
  111.     5.2.6 Pfizer (US)
  112.       5.2.6.1 Financial Overview
  113.       5.2.6.2 Products Offered
  114.       5.2.6.3 Key Developments
  115.       5.2.6.4 SWOT Analysis
  116.       5.2.6.5 Key Strategies
  117.     5.2.7 Bayer (DE)
  118.       5.2.7.1 Financial Overview
  119.       5.2.7.2 Products Offered
  120.       5.2.7.3 Key Developments
  121.       5.2.7.4 SWOT Analysis
  122.       5.2.7.5 Key Strategies
  123.     5.2.8 Roche (CH)
  124.       5.2.8.1 Financial Overview
  125.       5.2.8.2 Products Offered
  126.       5.2.8.3 Key Developments
  127.       5.2.8.4 SWOT Analysis
  128.       5.2.8.5 Key Strategies
  129.     5.2.9 Sanofi (FR)
  130.       5.2.9.1 Financial Overview
  131.       5.2.9.2 Products Offered
  132.       5.2.9.3 Key Developments
  133.       5.2.9.4 SWOT Analysis
  134.       5.2.9.5 Key Strategies
  135.   5.3 Appendix
  136.     5.3.1 References
  137.     5.3.2 Related Reports
  138. 6 LIST OF FIGURES
  139.   6.1 MARKET SYNOPSIS
  140.   6.2 US MARKET ANALYSIS BY TYPE
  141.   6.3 US MARKET ANALYSIS BY DIAGNOSIS METHOD
  142.   6.4 US MARKET ANALYSIS BY TREATMENT
  143.   6.5 US MARKET ANALYSIS BY END USER
  144.   6.6 KEY BUYING CRITERIA OF CONSTRUCTION
  145.   6.7 RESEARCH PROCESS OF MRFR
  146.   6.8 DRO ANALYSIS OF CONSTRUCTION
  147.   6.9 DRIVERS IMPACT ANALYSIS: CONSTRUCTION
  148.   6.10 RESTRAINTS IMPACT ANALYSIS: CONSTRUCTION
  149.   6.11 SUPPLY / VALUE CHAIN: CONSTRUCTION
  150.   6.12 CONSTRUCTION, BY TYPE, 2024 (% SHARE)
  151.   6.13 CONSTRUCTION, BY TYPE, 2024 TO 2035 (USD Million)
  152.   6.14 CONSTRUCTION, BY DIAGNOSIS METHOD, 2024 (% SHARE)
  153.   6.15 CONSTRUCTION, BY DIAGNOSIS METHOD, 2024 TO 2035 (USD Million)
  154.   6.16 CONSTRUCTION, BY TREATMENT, 2024 (% SHARE)
  155.   6.17 CONSTRUCTION, BY TREATMENT, 2024 TO 2035 (USD Million)
  156.   6.18 CONSTRUCTION, BY END USER, 2024 (% SHARE)
  157.   6.19 CONSTRUCTION, BY END USER, 2024 TO 2035 (USD Million)
  158.   6.20 BENCHMARKING OF MAJOR COMPETITORS
  159. 7 LIST OF TABLES
  160.   7.1 LIST OF ASSUMPTIONS
  161.     7.1.1
  162.   7.2 US MARKET SIZE ESTIMATES; FORECAST
  163.     7.2.1 BY TYPE, 2025-2035 (USD Million)
  164.     7.2.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  165.     7.2.3 BY TREATMENT, 2025-2035 (USD Million)
  166.     7.2.4 BY END USER, 2025-2035 (USD Million)
  167.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  168.     7.3.1
  169.   7.4 ACQUISITION/PARTNERSHIP
  170.     7.4.1

US Construction Market Segmentation

Construction By Type (USD Million, 2025-2035)

  • Functional Paraganglioma
  • Non-Functional Paraganglioma
  • Metastatic Paraganglioma

Construction By Diagnosis Method (USD Million, 2025-2035)

  • Imaging Techniques
  • Biopsy
  • Blood Tests

Construction By Treatment (USD Million, 2025-2035)

  • Surgery
  • Radiation Therapy
  • Chemotherapy
  • Targeted Therapy

Construction By End User (USD Million, 2025-2035)

  • Hospitals
  • Diagnostic Laboratories
  • Research Institutes

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions